Physician

Sunita Kammila Penmatcha, M.D.

According to 2025 Medicare claims, Sunita Penmatcha, M.D. (NPI: 1407065006) practices rheumatology in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Scott, IA. This provider's primary affiliated billing organization is RHEUMATOLOGY ASSOCIATES, PC (NPI: 1851578868; TIN: 261643846) and primary practice location at 52722-1624. Penmatcha is affiliated with the Genesis Accountable Care Organization, LLC. (ACO ID: A4799) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Penmatcha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 455 traditional Medicare patients, billed 151,416 HCPCS/CPT codes, and received $1,413,863 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,018 prescription claims across 453 beneficiaries totaling $1,437,117 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 25 records totaling $587. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $881,291 to $1,413,863. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $493,446 to $1,437,117. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	360	67,553	$881,291
2016	375	54,669	$986,525
2017	375	45,945	$846,311
2018	389	40,903	$771,284
2019	376	61,093	$860,006
2020	360	71,912	$933,717
2021	383	76,269	$1,017,199
2022	345	86,821	$1,060,897
2023	336	93,072	$1,042,184
2024	455	151,416	$1,413,863

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	227	1,997	$493,446
2016	244	2,155	$485,516
2017	247	2,177	$637,388
2018	255	2,197	$542,797
2019	347	2,596	$594,276
2020	342	2,864	$934,847
2021	366	2,858	$1,170,743
2022	352	2,685	$1,033,106
2023	369	2,597	$1,113,226
2024	453	3,018	$1,437,117

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	325	749	$85
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	285	537	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	270	596	$8
84460	Liver enzyme (sgpt), level	184	398	$5
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	263	445	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	39	1,260	$306,091
Enbrel Mini	Etanercept	39	1,092	$303,806
Otezla	Apremilast	27	810	$136,427
Rinvoq	Upadacitinib	19	570	$133,859
Xeljanz Xr	Tofacitinib Citrate	20	600	$115,971

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$587	Teva Pharmaceuticals USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sunita Kammila Penmatcha, M.D.?

Tedicare shows public-source Medicare data for Sunita Kammila Penmatcha, M.D. (NPI 1407065006), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sunita Kammila Penmatcha, M.D. have ACO affiliation data?

Sunita Kammila Penmatcha, M.D. is shown with ACO affiliation data for Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Sunita Kammila Penmatcha, M.D.?

Sunita Kammila Penmatcha, M.D. is linked to RHEUMATOLOGY ASSOCIATES, PC (billing NPI 1851578868) in the available physician profile data.

Does Sunita Kammila Penmatcha, M.D. have Open Payments data?

Sunita Kammila Penmatcha, M.D. has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.